Compare McKesson Corporation (MCK) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs YieldMax NVDA Option Income Strategy ETF — how do they compare? McKesson Corporation trades at $883.98 (market cap $105.14B), while YieldMax NVDA Option Income Strategy ETF trades at $13.06. The key difference: McKesson Corporation pays a 0.42% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and McKesson Corporation is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MCK | NVDY | |
|---|---|---|
Market Cap | $105.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $995.69 | $17.96 |
52-Week Low | $659.01 | $11.58 |
Enterprise Value | $111.67B | — |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
NVDY trades at $13.00, up 2.12% on the day, with technical indicators showing a bullish trend but overbought conditions on short-term RSI. The ETF generates income through weekly distributions, with recent dividends ranging from $0.09 to $0.15 per share. News highlights focus on its strategy of selling NVIDIA call options to fund payouts, sacrificing some upside for yield.
The outlook hinges on NVIDIA's volatility sustaining option premiums, offering high income but capping gains. Risks include underperformance vs. NVIDIA stock and fee drag. Analyst sentiment is mixed, weighing income benefits against opportunity costs, with institutional interest driven by yield-seeking investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
